Matevž Kmet started as a researcher in organic synthesis in Lek. Still within R&D, he led the project for the first e-submission of regulatory dossier for a generic drug to the FDA. Later, he moved to sales, being responsible for Lek sales to Japan, South Korea, USA, and Canada. In one of the largest investments funds in Slovenia, Aktiva Group, Matevž participated in valuation of various candidates for Aktiva Group venture fund investments. Simultaneously, he managed business development in Vitiva, one of Aktiva Group own start-up companies. Matevž then returned to the pharmaceutical industry. He worked for Pliva as the head of business development for the CEE region, and for Teva Pharmaceuticals as head of in-licencing for the EMEA region. Having a lot of experience in the CEE region, Matevž joined Bosnalijek in Bosnia and Herzegovina to help establishing corporate business and strategic development, which he then also lead. The entrepreneurial part of Matevž’s career was in Unafarm, a pharmaceutical company supplying value-added generic drugs to the Balkan countries. Matevž founded Unafarm together with a few colleagues from the industry, and acquired financing from both local private capital and a venture capital fund, co-financed by the EU. Currently, Matevž is working as the head of business development in Acies Bio, a successful, highly innovative Slovenian-based biotech company.
Matevž Kmet je začel kot raziskovalec v organski sintezi v Leku. Še vedno v R & D, je vodil projekt za prvo e-predložitev regulativne dokumentacije za generično zdravilo za FDA. Kasneje se je preselil v prodajo, odgovoren za prodajo Leka na Japonsko, Južno Korejo, ZDA in Kanado. Matevž je v enem od največjih investicijskih skladov v Sloveniji, Skupini Aktiva, sodeloval pri vrednotenju različnih kandidatov za naložbe tveganega kapitala skupine Aktiva. Hkrati je vodil poslovni razvoj v družbi Vitiva, ki je ena od lastnih zagonskih družb skupine Aktiva. Matevž se je nato vrnil v farmacevtsko industrijo. Delal je za Plivo kot vodja razvoja poslovanja za regijo Srednje in Vzhodne Evrope ter za Teva Pharmaceuticals kot vodja licence za regijo EMEA. Matevž se je z bogatimi izkušnjami v regiji Srednje in Vzhodne Evrope pridružil podjetju Bosnalijek v Bosni in Hercegovini za pomoč pri vzpostavljanju korporativnega poslovanja in strateškega razvoja, ki ga je nato vodil. Podjetniški del Matevževe kariere ga je vodil v Unafarm, farmacevtsko družbo, ki dobavlja generična zdravila z dodano vrednostjo v balkanske države. Matevž je skupaj z nekaj kolegi iz industrije ustanovil podjetje Unafarm in pridobil financiranje iz lokalnega zasebnega kapitala in sklada tveganega kapitala, ki ga sofinancira EU. Trenutno Matevž deluje kot vodja razvoja poslovanja v podjetju Acies Bio, uspešni, zelo inovativni slovenski biotehnološki družbi.